肠道微生态治疗肠易激综合征的效果分析

Analysis the result for intestinal microecology treatment irritable bowel syndrome

目的:探讨肠道微生态治疗肠易激综合征效果。方法:选取肠易激综合征患者58例,分为干预组和对照组。干预组予以双歧杆菌四联活菌片(思连康) 3片1.5 g,3次/d,联合马来酸曲美布汀(瑞健) 0.2 g,3次/d。对照组予以马来酸曲美布汀(瑞健) 0.2 g,3次/d。均治疗4周。停药1周后分别比较两组的有效率,排便次数,粪便性状异常比例及腹胀评分。结果:停药1周后干预组有效率高于对照组,差异具有统计学意义(P<0.05)。与治疗前比较,停药1周后干预组和对照组排便次数和粪便性状异常比例均明显下降,差异具有统计学意义(P<0.05);治疗后干预组排便次数和粪便性状异常低于对照组,差异具有统计学意义(P<0.05)。与治疗前比较,治疗后干预组和对照组腹胀评分均明显下降,但治疗后干预组和对照组腹胀评分比较,两组相比差异无统计学意义(P>0.05)。结论:补充益生菌可能可以改善肠易激综合征患者的排便次数及粪便性状等症状。

Objective To investigate the result of intestinal microecology treatment irritable bowel syndrome.Method 58 patients with irritable bowel syndrome were enrolled and divided into intervention group and control group.The intervention group received 3 pieces,1.5 g of Bifidobacterium quadruple live bacteria tablets(Si Liankang),combined with trimebutine maleate(Ruijian)3 times a day,and The control group was only given 0.2 g of trimebutine maleate(Ruijian)3 times a day.All treatments after 4 weeks stopped the drug,the effective rate,the number of bowel movements,the abnormal proportion of fecal traits and the bloating score were compared.Results After 1 week of withdrawal,the effective rate of the intervention group was higher than the control group,and the difference was statistically significant(P<0.05).Compared with before treatment,after 1 week of withdrawal,the frequency of defecation and the abnormality of fecal traits in the intervention group and the control group were significantly decreased(P<0.05).After treatment,the number of interventions and fecal traits were lower than the control group,the difference was statistically significant(P<0.05).Compared with before treatment,the bloating scores of the intervention group and the control group were significantly decreased after treatment,but there was no significant difference in the bloating score between the intervention group and the control group after treatment(P>0.05).Conclusion Supplementation of probiotics may improve the number of bowel movements and fecal traits in patients with irritable bowel syndrome.